Trial Profile
A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Phase IV Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms INFORM
- Sponsors AstraZeneca
- 27 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.
- 07 Jul 2011 Results presented at the 14th Annual Congress of the European Respiratory Society.
- 05 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.